Evidence map›Paper›PMID 37914736›Full record

ArticleScientific reports2023

MTHFR C677T and A1298C polymorphism's effect on risk of colorectal cancer in Lynch syndrome.

Mariann Unhjem Wiik, Mia Negline, Vidar Beisvåg, Matthew Clapham, Elizabeth Holliday, Nuria Dueñas, Joan Brunet, Marta Pineda, Nuria Bonifaci, Stefan Aretz and 9 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 5 countries.

Mariann Unhjem WiikResearch Unit, Ålesund Hospital, Møre and Romsdal Hospital Trust, Ålesund, Norway.
Mia NeglineSchool of Biomedical Science and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia.
Vidar BeisvågDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway.
Matthew ClaphamSchool of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia.
Elizabeth HollidaySchool of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia.
Nuria DueñasHereditary Cancer Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Joan BrunetHereditary Cancer Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Marta PinedaHereditary Cancer Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Nuria BonifaciHereditary Cancer Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Stefan AretzInstitute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany.
Hannah KlinkhammerInstitute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.
Isabel SpierInstitute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany.
Claudia PerneInstitute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany.
Andreas MayrInstitute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.
Laura ValleHereditary Cancer Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
Jan LubinskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Wenche SjursenDepartment of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway.
Rodney J ScottSchool of Biomedical Science and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle and Hunter Medical Research Institute, Newcastle, Australia.
Bente A Talseth-PalmerResearch Unit, Ålesund Hospital, Møre and Romsdal Hospital Trust, Ålesund, Norway. bente.talseth-palmer@newcastle.edu.au.
Hunter Medical Research Institute · AUInstitut Català d'Oncologia · ESSt Olav's University Hospital · NOUniversity Hospital Bonn · DEUniversity of Bonn · DECentro de Investigación Biomédica en Red de Cáncer · ESNorwegian University of Science and Technology · NOPomeranian Medical University · PLUniversity of Newcastle Australia · AUZimmer Biomet (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lynch syndrome (LS) is characterised by an increased risk of developing colorectal cancer (CRC) and other extracolonic epithelial cancers. It is caused by pathogenic germline variants in DNA mismatch repair (MMR) genes or the EPCAM gene, leading to a less functional DNA MMR system. Individuals diagnosed with LS (LS individuals) have a 10-80% lifetime risk of developing cancer. However, there is considerable variability in the age of cancer onset, which cannot be attributed to the specific MMR gene or variant alone. It is speculated that multiple genetic and environmental factors contribute to this variability, including two single nucleotide polymorphisms (SNPs) in the methylenetetrahydrofolate reductase (MTHFR) gene: C677T (rs1801133) and A1298C (rs1801131). By decreasing MTHFR activity, these SNPs theoretically reduce the silencing of DNA repair genes and increase the availability of nucleotides for DNA synthesis and repair, thereby protecting against early-onset cancer in LS. We investigated the effect of these SNPs on LS disease expression in 2,723 LS individuals from Australia, Poland, Germany, Norway and Spain. The association between age at cancer onset and SNP genotype (risk of cancer) was estimated using Cox regression adjusted for gender, country and affected MMR gene. For A1298C (rs1801131), both the AC and CC genotypes were significantly associated with a reduced risk of developing CRC compared to the AA genotype, but no association was seen for C677T (rs1801133). However, an aggregated effect of protective alleles was seen when combining the alleles from the two SNPs, especially for LS individuals carrying 1 and 2 alleles. For individuals with germline pathogenic variants in MLH1, the CC genotype of A1298C was estimated to reduce the risk of CRC significantly by 39% (HR = 0.61, 95% CI 0.42, 0.89, p = 0.011), while for individuals with pathogenic germline MSH2 variants, the AC genotype (compared to AA) was estimated to reduce the risk of CRC by 26% (HR = 0.66, 95% CI 0.53, 0.83, p = 0.01). In comparison, no association was observed for C677T (rs1801133). In conclusion, our study suggests that combining the MMR gene information with the MTHFR genotype, including the aggregated effect of protective alleles, could be useful in developing an algorithm that estimates the risk of CRC in LS individuals.

Indexed as

Colorectal NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisCase-Control StudiesDNAGenetic Predisposition to DiseaseGenotypeHumansMethylenetetrahydrofolate Reductase (NADPH2)Polymorphism, Single NucleotideDNAMethylenetetrahydrofolate Reductase (NADPH2)MTHFR protein, human

Identifiers

PMID37914736
PMCPMC10620134
OpenAlexW4388130548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.